Fluorouracil + Vinorelbine

The combination of fluorouracil (5-FU) and vinorelbine represents a chemotherapy regimen used primarily in cancer treatment. This combination has been studied in various clinical settings, particularly for metastatic breast cancer and carcinoma of unknown primary. ## Pharmacological Profile Vinorelbine is a semi-synthetic vinca alkaloid that works by interfering with tubulin polymerization, thereby inhibiting mitosis at metaphase[2]. It's classified as a mitotic spindle poison that prevents chromosomal segregation during cell division[2]. When combined with 5-fluorouracil, this regimen creates a multi-targeted approach to cancer treatment. The combination is typically administered intravenously, with specific dosing schedules depending on the cancer type and treatment protocol. ## Clinical Applications The fluorouracil + vinorelbine combination has shown efficacy in several cancer types: **Metastatic Breast Cancer** In a Phase I-II study, the combination of vinorelbine, 5-fluorouracil, and folinic acid demonstrated significant activity as first-line treatment in patients with metastatic breast cancer[1]. The study reported: - Objective responses in 24 of 39 evaluable patients (62%, with 95% CI: 47% to 77%) - Complete responses in 7 patients (18%) - Partial responses in 17 patients (44%) - Stable disease in 9 patients (23%) - Disease progression in only 6 patients (15%)[1] The median response duration was 10 months (range 6 to 24+ months) and median time to progression was 8 months[1]. **Carcinoma of Unknown Primary (CUP)** The ViFuP regimen (vinorelbine, cisplatin, and continuous infusion 5-fluorouracil) has been evaluated in patients with carcinoma of unknown primary[3]. This regimen showed: - Objective responses in 27% of patients (6 partial responses and 1 complete response) - Stable disease in 35% of patients - Overall clinical benefit in 52% of patients[3] ## Dosing Regimens Different dosing schedules have been used in clinical studies: **For Metastatic Breast Cancer:** - 5-fluorouracil: 350 mg/m² IV on days 1-3 - Folinic acid: 100 mg/m² IV on days 1-3 - Vinorelbine: 25 mg/m² IV on days 1 and 3[1] This regimen is typically administered every three weeks on an outpatient basis. **For Carcinoma of Unknown Primary (ViFuP regimen):** - Vinorelbine: 20 mg on days 1 and 3 - Continuous infusion 5-fluorouracil: 200 mg/m² days 1-21 - Cisplatin: 60 mg/m² day 1[3] This course is repeated every 21 days for up to six cycles, with continuous 5-FU infusion continued in case of response or clinical benefit. ## Safety Profile The most common adverse effects observed with this combination include: **Hematological toxicities:** - Granulocytopenia (grade 4 in 77% of patients in one study) - Neutropenia (grade 3-4 in 11% of patients in another study) - Febrile neutropenia requiring hospitalization **Gastrointestinal effects:** - Mild to moderate nausea, vomiting, and anorexia - Constipation (including severe "ileus-like syndrome" at higher vinorelbine doses) **Other effects:** - Moderate alopecia (in about one-third of patients) - Anemia (grade 3-4 in 3% of patients in one study) The combination is generally described as "subjectively well tolerated" with manageable side effects[1][3]. The fluorouracil + vinorelbine combination represents an effective chemotherapy option that offers efficacy comparable to other first-line regimens while maintaining a favorable toxicity profile, making it a valuable treatment approach for certain cancer types.

Other names

5-FU + VinorelbineVinorelbine + 5-FU